NRAS and melanoma: Using Roadmap data from primary melanocytes, and BRAF and NRAS mutant melanocytes, the authors noted that as melanocytes progressed towards melanoma, BRAF mutants exhibited a global decrease in the number of bivalent domains, while NRAS mutants had an increase.